

# Platelet aggregates, a marker of severe COVID-19 disease

Alexandros Rampotas , Sue Pavord

Haematology Department,  
Oxford University Hospitals NHS  
Foundation Trust, Oxford, UK

## Correspondence to

Dr Alexandros Rampotas,  
Haematology Department,  
Oxford University Hospitals  
NHS Foundation Trust, Oxford  
OX3 9DU, UK; alexandros.  
rampotas@ouh.nhs.uk


Received 9 July 2020  
Revised 16 September 2020  
Accepted 1 October 2020  
Published Online First  
16 October 2020

## ABSTRACT

Thrombocytopenia is common in an intensive care unit (ICU) setting due to endogenous and iatrogenic factors. Despite that, thrombocytopenia in patients with severe COVID-19 infections is surprisingly uncommon. By examining the blood film of 20 ICU patients with COVID-19, we observed the presence of platelet aggregates and macrothrombocytes indicating increased platelet activity. We compared these findings with 20 blood films of non-severe COVID-19 cases where these findings were absent. These morphology features could be consistent with severe COVID-19 infection and is further evidence of the important role that platelets play when COVID-19 manifests with thrombotic complications or respiratory failure.

Significant thrombocytopenia in patients with severe COVID-19 infection is surprisingly uncommon, with only around 5% of hospitalised patients and 8% of those on the intensive care unit (ICU) developing a platelet count below  $100 \times 10^9/L$ .<sup>1</sup> This is inconsistent with our expectation of patients with serious infective/inflammatory conditions where endogenous and iatrogenic factors affect the platelet count; for example, liver impairment, sepsis, heparin, antibiotics, antivirals and other commonly used agents.<sup>2</sup>

The coagulopathy associated with COVID-19, with very elevated D-dimers, is different from classic disseminated intravascular coagulation (DIC), where platelet and fibrinogen levels fall as a result of consumption in the coagulation process. Autopsies from patients who have died with COVID-19 pneumonia show microvascular thrombosis throughout the small vessels of the lungs and alveolar capillaries, suggesting thrombi are likely to




**Figure 2** Peripheral films showing platelet aggregates (yellow arrows).

be the end point of localised inflammation.<sup>3</sup> This inflammation points toward an immune response which can lead to dysregulation of P-selectin, fibrin, von Willebrand factor and d-dimers resulting in a hypercoagulable state.<sup>4 5</sup> Overt DIC can also develop after prolonged hospitalisation, while a fall in platelet count has been associated with severe COVID-19 disease, high mortality and indicates a high intravascular clotting risk.<sup>4 6-9</sup>

To help understand the relative preservation of the platelet count, we examined 20 random blood films from patients undergoing invasive ventilation comparing those to 20 random films from stable patients with COVID-19 who had ward-based care or were discharged after the initial assessment, and identified the nadir platelet count reached by all patients positive for COVID-19 hospitalised in our centre. The diagnosis of COVID-19 was made either via a throat swab or PCR of bronchioalveolar lavage following high clinical suspicion.

There were 575 hospitalised patients with confirmed COVID-19 from 10 March 2020 to 20 June 2020 in Oxford University Hospitals. Overall, the nadir platelet counts are shown in table 1. Only 8% had platelet counts  $<100 \times 10^9/L$  and 2.2% had counts  $<50 \times 10^9/L$ . Even in non-survivors, significant thrombocytopenia was only seen in 6% and in 9% of ICU patients with COVID-19.

Examination of the peripheral blood film (figure 1) showed the presence of macrothrombocytes in all films, with median Mean Platelet Volume (MPV) of 10.65 fL (IQR: 10.35–11.47), dense granules and occasional large proplatelet fragments. Large platelet aggregates of around 7–30 platelets throughout the film were seen in all the blood films from the ICU patients (figures 1 and 2). This finding was not present in any of the 20 comparative blood films from stable



**Figure 1** Peripheral films showing platelet aggregates (yellow arrows) and macrothrombocytes (red arrows).



© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Rampotas A, Pavord S. *J Clin Pathol* 2021;**74**:750–751.

**Table 1** Nadir platelet count of patients diagnosed with COVID-19 treated in ICU and non-ICU (ward)

Platelet count	<50×10 <sup>9</sup> /L	50–100×10 <sup>9</sup> /L	100–150×10 <sup>9</sup> /L	>150×10 <sup>9</sup> /L	Total
Ward survivors	2	10	54	275	341
Ward non-survivors	4	17	40	98	159
<b>Ward total</b>	<b>6</b>	<b>27</b>	<b>94</b>	<b>373</b>	<b>500</b>
ICU survivors	0	2	7	41	50
ICU non-survivors	7	3	3	12	25
<b>ICU total</b>	<b>7</b>	<b>5</b>	<b>10</b>	<b>53</b>	<b>75</b>
<b>Grand total</b>	<b>13</b>	<b>32</b>	<b>104</b>	<b>426</b>	<b>575</b>

ICU, intensive care unit.

patients with COVID-19, while their MPV was 10.3 fL (IQR: 9.91–11.25).

All ICU patients had a degree of anaemia with a median haemoglobin of 86.5 g/L (IQR: 72.25–98.25), with polychromasia and nucleated red blood cells present in all films. None of the films showed schistocytes. Their duration of illness and relevant medication are shown in [table 2](#).

This study suggests a high turnover of platelets, with macrothrombocytes consistent with increased production, and the relative preservation of the platelet count due to a balance of increased consumption, in microangiopathic thrombosis, and production, likely driven by the effect of the cytokine storm enhancing hepatic production of thrombopoietin. The dense granules and platelet aggregates present in all ICU patients suggest heightened platelet activity, and the absence of red cell fragments is in keeping with the microvascular thrombi being a result of inflammation rather than a typical thrombotic microangiopathy. These changes can be seen in ICU patients, but they are almost always associated with DIC and concurrent thrombocytopenia.<sup>10</sup>

The large proplatelet fragments may indicate abnormal fragmentation of megakaryocytes. The lungs have been identified as a primary site of terminal platelet production, accounting for approximately 50% of total platelet production.<sup>11</sup> One could postulate that the damage to the lung results in disordered megakaryocyte fragmentation or disruption of the normal filtration of megakaryocytes in the pulmonary circulation, leaving increased megakaryocytes in the blood. Indeed, a large number of megakaryocytes have been found in the pulmonary capillaries at autopsy.<sup>12</sup> Additionally, megakaryocytes are a rich source of cytokines and growth factors that have the potential to influence inflammatory or fibrotic lung diseases. Interestingly RNA-sequence analysis has revealed that lung megakaryocytes

**Table 2** Intensive Treatment Unit (ITU) patient characteristics that had blood film examined

Characteristics	
Age (years, median)	62 (IQR: 55–74)
Antiplatelets (no of patients)	4/20
Anticoagulation (no of patients)	0/20
Duration of illness (days, median)	9 (IQR: 8–16)
Previous history of arterial or venous thrombosis (no of patients)	0/20

are skewed toward an innate immunity function.<sup>13</sup> Mechanical ventilation can aggravate this process and lead to increased inflammation as the inflation and deflation of the lung can induce proplatelet cleavage and release of proinflammatory particles.<sup>14</sup>

Despite the relatively normal platelet counts seen in patients with severe COVID-19 disease, blood film appearances support significant involvement of platelets in the disease process. The presence of platelet aggregates may be a useful marker of worsening disease.

**Handling editor** Mary Frances McMullin.

**Twitter** Alexandros Rampotas @ARampotas

**Contributors** AR and SP conceived the idea, collected the data, drafted and critically evaluated the manuscript, and approved the final version of this manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iD**

Alexandros Rampotas <http://orcid.org/0000-0002-2681-5860>

## REFERENCES

- Huang C, Wang Y, Li X, *et al*. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020;395:497–506.
- Hui P, Cook DJ, Lim W, *et al*. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. *Chest* 2011;139:271–8.
- Fox SE, Akmatbekov A, Harbert JL, *et al*. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from new Orleans. *Medrxiv* 2020.
- Gavriatopoulou M, Korompoki E, Fotiou D, *et al*. Organ-Specific manifestations of COVID-19 infection. *Clin Exp Med* 2020. doi:10.1007/s10238-020-00648-x. [Epub ahead of print: 27 Jul 2020].
- Grobler C, Maphumulo SC, Grobbelaar LM, *et al*. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. *Int J Mol Sci* 2020;21:5168.
- Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin Chim Acta* 2020;506:145–8.
- Yang X, Yang Q, Wang Y, *et al*. Thrombocytopenia and its association with mortality in patients with COVID-19. *J Thromb Haemost* 2020;18:1469–72.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, *et al*. Hematological findings and complications of COVID-19. *Am J Hematol* 2020;95:834–47.
- Bao C, Tao X, Cui W, *et al*. SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. *Exp Hematol Oncol* 2020;9:16.
- Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. *Mayo Clin Proc* 2003;78:869–81.
- Lefrançois E, Looney MR. Platelet biogenesis in the lung circulation. *Physiology* 2019;34:392–401.
- Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, *et al*. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. *J Thromb Haemost* 2020;18:1517–9.
- Lefrançois E, Ortiz-Muñoz G, Caudrillier A, *et al*. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* 2017;544:105–9.
- Mutschler DK, Larsson AO, Basu S, *et al*. Effects of mechanical ventilation on platelet microparticles in bronchoalveolar lavage fluid. *Thromb Res* 2002;108:215–20.